Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
Gelesis' LIGHT-UP clinical trial demonstrated that GS200, an oral superabsorbent hydrogel, effectively aids weight loss in adults with prediabetes or type 2 diabetes. About 60% of participants experienced at least a 5% decrease in body weight, averaging a loss of 11% (about 23 pounds) in just six months. Furthermore, roughly one-third were 'super responders,' losing over 10% of their body weight. The safety profile of GS200 was comparable to the placebo, indicating a promising new avenue in weight management for at-risk populations.
PureTech Health and its Founded Entity, Gelesis Holdings, presented preclinical data at the World of Microbiome Conference in Vienna. The study showed that Gelesis’ proprietary superabsorbent hydrogel, Gel-B, when added to a high-fat diet, positively influenced gut microbiota, enhancing metabolic health indicators such as weight and glucose control. Notably, Gel-B promoted increased growth of Akkermansia muciniphila, beneficial for gut health. The findings suggest Gel-B's therapeutic potential extends beyond mere space occupation in the digestive system.
PureTech Health reported a solid capital base with cash equivalents of $465.7 million as of December 31, 2021. The company has a robust pipeline featuring 27 therapeutics, with 11 clinical trials initiated in 2021. Notably, PureTech's Founded Entities have achieved significant milestones, including FDA marketing approvals for two products. The company is evaluating capital allocation strategies to enhance shareholder value, including potential returns through dividends or buybacks. Its cash runway extends into 2025, supporting ongoing development across its pipeline.
PureTech Health announces the publication of Phase 1a/1b study results for its lead program VE303, a defined bacterial consortium candidate for preventing recurrent Clostridium difficile infection, in Cell Host & Microbe. The study demonstrated VE303's safety and tolerability, highlighting improved colonization dynamics through specific dosing regimens. Positive topline results from the Phase 2 CONSORTIUM trial were previously reported in October 2021, showing a 31.7% absolute risk reduction in recurrence rates. Three abstracts will be presented at Digestive Disease Week 2022.
Vedanta Biosciences announced the publication of Phase 1a/1b study results for VE303, a bacterial consortium candidate for preventing Clostridium difficile infection, in Cell Host & Microbe. The study showed VE303 was well-tolerated and effectively colonized the gut when dosed over multiple days. Preparations for Phase 3 trials are underway following positive topline Phase 2 results published in 2021, which revealed a 31.7% reduction in CDI recurrence rates. Three abstracts related to VE303 and VE202 will be presented at Digestive Disease Week 2022.
PureTech Health announced that Akili’s AKL-T03 digital therapeutic demonstrated a statistically significant improvement in sustained attention in adults with major depressive disorder (MDD) when combined with antidepressant therapy, as published in the American Journal of Psychiatry. The STARS-MDD trial involved 80 adults and showed a 0.005 significance level. This digital therapeutic builds on the technology of EndeavorRx, already FDA-cleared for treating children with ADHD. Akili aims to fill a gap in treating cognitive impairments associated with depression, a condition affecting over 16 million Americans.
PureTech Health has announced the publication of groundbreaking research demonstrating its Glyph technology, which enhances the oral bioavailability of buprenorphine by up to 20-fold. This technology utilizes lymphatic transport, which bypasses first-pass liver metabolism, significantly improving drug delivery for conditions that require effective opioid replacement therapy. Published in Frontiers in Pharmacology, this study highlights the potential of Glyph technology to revolutionize treatment approaches for various clinically validated drugs.
PureTech Health plans to publish its annual report and financial results on April 26, 2022, at 2:00 AM EDT. This report will detail the financial status as of December 31, 2021, and include the cash balance for Q1 2022. A conference call for discussion will occur on the same day at 9:00 AM EDT. The company aims to highlight progress in its pipeline and its commitment to environmental, social, and governance practices. PureTech is focused on developing treatments for serious diseases and has 25 therapeutic candidates in its pipeline.
PureTech Health announced the appointment of Sharon Barber-Lui as a non-executive director and chair of the Audit Committee. With over 20 years at Merck & Co., Barber-Lui brings extensive experience in finance and operations. She previously led U.S. Oncology Portfolio Market Strategy at Merck and currently serves at EQRx. Her expertise is expected to enhance the board's strategic vision, particularly for PureTech's advanced clinical programs.
PureTech Health announces Jon David as the new Chief Product Officer of its Founded Entity, Akili Interactive. With over 20 years in the gaming industry, David is expected to drive Akili's product pipeline, developing innovative cognitive treatments that feel like high-end entertainment. His leadership experience includes positions at Glu Mobile and PopCap Games, where he contributed to hit franchises. This strategic appointment underscores Akili's commitment to merging entertainment with therapeutic solutions as it prepares for its merger with Social Capital Suvretta Holdings Corp. I.